Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Akt-1 and Akt-2 Differentially Regulate the Development of Experimental Autoimmune Encephalomyelitis by Controlling Proliferation of Thymus-Derived Regulatory T Cells.

Ouyang S, Zeng Q, Tang N, Guo H, Tang R, Yin W, Wang A, Tang H, Zhou J, Xie H, Langdon WY, Yang H, Zhang J.

J Immunol. 2019 Mar 1;202(5):1441-1452. doi: 10.4049/jimmunol.1701204. Epub 2019 Jan 28.

PMID:
30692211
2.

Regulation of immune responses by E3 ubiquitin ligase Cbl-b.

Tang R, Langdon WY, Zhang J.

Cell Immunol. 2019 Jun;340:103878. doi: 10.1016/j.cellimm.2018.11.002. Epub 2018 Nov 7. Review.

PMID:
30442330
3.

Cbl Ubiquitin Ligases Control B Cell Exit from the Germinal-Center Reaction.

Li X, Gadzinsky A, Gong L, Tong H, Calderon V, Li Y, Kitamura D, Klein U, Langdon WY, Hou F, Zou YR, Gu H.

Immunity. 2018 Mar 20;48(3):530-541.e6. doi: 10.1016/j.immuni.2018.03.006.

4.

Regulation of C-Type Lectin Receptor-Mediated Antifungal Immunity.

Tang J, Lin G, Langdon WY, Tao L, Zhang J.

Front Immunol. 2018 Feb 1;9:123. doi: 10.3389/fimmu.2018.00123. eCollection 2018. Review.

5.

Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy.

Taylor SJ, Langdon WY.

Mol Cell Oncol. 2017 Sep 19;4(6):e1378156. doi: 10.1080/23723556.2017.1378156. eCollection 2017.

6.

Sleeping through the storm: Preventing myelosuppression with quizartinib.

Taylor SJ, Langdon WY.

Oncotarget. 2017 Sep 30;8(51):88255-88256. doi: 10.18632/oncotarget.21395. eCollection 2017 Oct 24. No abstract available.

7.

Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.

Taylor SJ, Duyvestyn JM, Dagger SA, Dishington EJ, Rinaldi CA, Dovey OM, Vassiliou GS, Grove CS, Langdon WY.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaam8060. doi: 10.1126/scitranslmed.aam8060.

PMID:
28794285
8.

CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.

Lv K, Jiang J, Donaghy R, Riling CR, Cheng Y, Chandra V, Rozenova K, An W, Mohapatra BC, Goetz BT, Pillai V, Han X, Todd EA, Jeschke GR, Langdon WY, Kumar S, Hexner EO, Band H, Tong W.

Genes Dev. 2017 May 15;31(10):1007-1023. doi: 10.1101/gad.297135.117. Epub 2017 Jun 13.

9.

Inhibition of CBLB protects from lethal Candida albicans sepsis.

Wirnsberger G, Zwolanek F, Asaoka T, Kozieradzki I, Tortola L, Wimmer RA, Kavirayani A, Fresser F, Baier G, Langdon WY, Ikeda F, Kuchler K, Penninger JM.

Nat Med. 2016 Aug;22(8):915-23. doi: 10.1038/nm.4134. Epub 2016 Jul 18.

10.

Targeting CBLB as a potential therapeutic approach for disseminated candidiasis.

Xiao Y, Tang J, Guo H, Zhao Y, Tang R, Ouyang S, Zeng Q, Rappleye CA, Rajaram MV, Schlesinger LS, Tao L, Brown GD, Langdon WY, Li BT, Zhang J.

Nat Med. 2016 Aug;22(8):906-14. doi: 10.1038/nm.4141. Epub 2016 Jul 18.

11.

Dasatinib promotes the activation of quiescent hematopoietic stem cells in mice.

Duyvestyn JM, Taylor SJ, Dagger SA, Langdon WY.

Exp Hematol. 2016 May;44(5):410-421.e5. doi: 10.1016/j.exphem.2016.02.008. Epub 2016 Feb 26.

12.

Human IgG1 antibodies suppress angiogenesis in a target-independent manner.

Bogdanovich S, Kim Y, Mizutani T, Yasuma R, Tudisco L, Cicatiello V, Bastos-Carvalho A, Kerur N, Hirano Y, Baffi JZ, Tarallo V, Li S, Yasuma T, Arpitha P, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ruvo M, Sandomenico A, Nozaki M, Ijima R, Kaneko H, Ogura Y, Terasaki H, Ambati BK, Leusen JH, Langdon WY, Clark MR, Armour KL, Bruhns P, Verbeek JS, Gelfand BD, De Falco S, Ambati J.

Signal Transduct Target Ther. 2016;1. pii: 15001. Epub 2016 Jan 28.

13.

Protein Tyrosine Phosphatase SHP-1 Modulates T Cell Responses by Controlling Cbl-b Degradation.

Xiao Y, Qiao G, Tang J, Tang R, Guo H, Warwar S, Langdon WY, Tao L, Zhang J.

J Immunol. 2015 Nov 1;195(9):4218-27. doi: 10.4049/jimmunol.1501200. Epub 2015 Sep 28.

14.

The targeting of human and mouse B lymphocytes by dasatinib.

Oksvold MP, Duyvestyn JM, Dagger SA, Taylor SJ, Forfang L, Myklebust JH, Smeland EB, Langdon WY.

Exp Hematol. 2015 May;43(5):352-363.e4. doi: 10.1016/j.exphem.2015.01.008. Epub 2015 Jan 29.

15.

E3 Ubiquitin Ligase Cbl-b Regulates Thymic-Derived CD4+CD25+ Regulatory T Cell Development by Targeting Foxp3 for Ubiquitination.

Zhao Y, Guo H, Qiao G, Zucker M, Langdon WY, Zhang J.

J Immunol. 2015 Feb 15;194(4):1639-45. doi: 10.4049/jimmunol.1402434. Epub 2015 Jan 5.

16.

Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.

Taylor SJ, Thien CB, Dagger SA, Duyvestyn JM, Grove CS, Lee BH, Gilliland DG, Langdon WY.

Exp Hematol. 2015 Mar;43(3):191-206.e1. doi: 10.1016/j.exphem.2014.11.009. Epub 2014 Dec 19.

17.

Lymphoid tissue and plasmacytoid dendritic cells and macrophages do not share a common macrophage-dendritic cell-restricted progenitor.

Sathe P, Metcalf D, Vremec D, Naik SH, Langdon WY, Huntington ND, Wu L, Shortman K.

Immunity. 2014 Jul 17;41(1):104-15. doi: 10.1016/j.immuni.2014.05.020.

18.

Loss of Cbl-PI3K interaction in mice prevents significant bone loss following ovariectomy.

Adapala NS, Holland D, Scanlon V, Barbe MF, Langdon WY, Tsygankov AY, Lorenzo JA, Sanjay A.

Bone. 2014 Oct;67:1-9. doi: 10.1016/j.bone.2014.06.013. Epub 2014 Jul 1.

19.

E3 ubiquitin ligase Cbl-b in innate and adaptive immunity.

Liu Q, Zhou H, Langdon WY, Zhang J.

Cell Cycle. 2014;13(12):1875-84. doi: 10.4161/cc.29213. Epub 2014 May 14. Review.

20.

Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.

Duyvestyn JM, Taylor SJ, Dagger SA, Orandle M, Morse HC 3rd, Thien CB, Langdon WY.

PLoS One. 2014 Apr 9;9(4):e94717. doi: 10.1371/journal.pone.0094717. eCollection 2014.

21.

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.

Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, Jamieson AM, Langdon WY, Ikeda F, Fededa JP, Cronin SJ, Nitsch R, Schultz-Fademrecht C, Eickhoff J, Menninger S, Unger A, Torka R, Gruber T, Hinterleitner R, Baier G, Wolf D, Ullrich A, Klebl BM, Penninger JM.

Nature. 2014 Mar 27;507(7493):508-12. doi: 10.1038/nature12998. Epub 2014 Feb 19.

22.

E3 ubiquitin ligase Cbl-b suppresses proallergic T cell development and allergic airway inflammation.

Qiao G, Ying H, Zhao Y, Liang Y, Guo H, Shen H, Li Z, Solway J, Tao E, Chiang YJ, Lipkowitz S, Penninger JM, Langdon WY, Zhang J.

Cell Rep. 2014 Feb 27;6(4):709-23. doi: 10.1016/j.celrep.2014.01.012. Epub 2014 Feb 6.

23.

Cbl-b: Roles in T Cell Tolerance, Proallergic T Cell Development, and Cancer Immunity.

Zhang J, Liu Q, Langdon WY.

Inflamm Cell Signal. 2014;1(4). pii: e146.

24.

T cell activation threshold regulated by E3 ubiquitin ligase Cbl-b determines fate of inducible regulatory T cells.

Qiao G, Zhao Y, Li Z, Tang PQ, Langdon WY, Yang T, Zhang J.

J Immunol. 2013 Jul 15;191(2):632-9. doi: 10.4049/jimmunol.1202068. Epub 2013 Jun 7.

25.

Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.

Taylor SJ, Dagger SA, Thien CB, Wikstrom ME, Langdon WY.

Blood. 2012 Nov 8;120(19):4049-57. doi: 10.1182/blood-2012-06-436675. Epub 2012 Sep 18.

26.

E3 ubiquitin ligase Cbl-b regulates Pten via Nedd4 in T cells independently of its ubiquitin ligase activity.

Guo H, Qiao G, Ying H, Li Z, Zhao Y, Liang Y, Yang L, Lipkowitz S, Penninger JM, Langdon WY, Zhang J.

Cell Rep. 2012 May 31;1(5):472-82.

27.

FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.

Langdon WY.

Crit Rev Oncog. 2012;17(2):199-209. Review.

PMID:
22471708
28.

Autophagic targeting of Src promotes cancer cell survival following reduced FAK signalling.

Sandilands E, Serrels B, McEwan DG, Morton JP, Macagno JP, McLeod K, Stevens C, Brunton VG, Langdon WY, Vidal M, Sansom OJ, Dikic I, Wilkinson S, Frame MC.

Nat Cell Biol. 2011 Dec 4;14(1):51-60. doi: 10.1038/ncb2386.

PMID:
22138575
29.

Tyrosine phosphorylated c-Cbl regulates platelet functional responses mediated by outside-in signaling.

Buitrago L, Langdon WY, Sanjay A, Kunapuli SP.

Blood. 2011 Nov 17;118(20):5631-40. doi: 10.1182/blood-2011-01-328807. Epub 2011 Oct 3.

30.

Incidence of c-Cbl mutations in human acute myeloid leukaemias in an Australian patient cohort.

Ghassemifar R, Thien CB, Finlayson J, Joske D, Cull GM, Augustson B, Langdon WY.

Pathology. 2011 Apr;43(3):261-5. doi: 10.1097/PAT.0b013e328343ca4b.

PMID:
21436637
31.

Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions.

Paolino M, Thien CB, Gruber T, Hinterleitner R, Baier G, Langdon WY, Penninger JM.

J Immunol. 2011 Feb 15;186(4):2138-47. doi: 10.4049/jimmunol.1003390. Epub 2011 Jan 19.

32.

Visualizing the role of Cbl-b in control of islet-reactive CD4 T cells and susceptibility to type 1 diabetes.

Hoyne GF, Flening E, Yabas M, Teh C, Altin JA, Randall K, Thien CB, Langdon WY, Goodnow CC.

J Immunol. 2011 Feb 15;186(4):2024-32. doi: 10.4049/jimmunol.1002296. Epub 2011 Jan 19.

33.

Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.

Rathinam C, Thien CB, Flavell RA, Langdon WY.

Cancer Cell. 2010 Oct 19;18(4):341-52. doi: 10.1016/j.ccr.2010.09.008.

34.

The loss of Cbl-phosphatidylinositol 3-kinase interaction perturbs RANKL-mediated signaling, inhibiting bone resorption and promoting osteoclast survival.

Adapala NS, Barbe MF, Langdon WY, Nakamura MC, Tsygankov AY, Sanjay A.

J Biol Chem. 2010 Nov 19;285(47):36745-58. doi: 10.1074/jbc.M110.124628. Epub 2010 Sep 17.

35.

Cbl-b is a novel physiologic regulator of glycoprotein VI-dependent platelet activation.

Daniel JL, Dangelmaier CA, Mada S, Buitrago L, Jin J, Langdon WY, Tsygankov AY, Kunapuli SP, Sanjay A.

J Biol Chem. 2010 Jun 4;285(23):17282-91. doi: 10.1074/jbc.M109.080200. Epub 2010 Apr 16.

36.

Cbl-phosphatidylinositol 3 kinase interaction differentially regulates macrophage colony-stimulating factor-mediated osteoclast survival and cytoskeletal reorganization.

Adapala NS, Barbe MF, Langdon WY, Tsygankov AY, Sanjay A.

Ann N Y Acad Sci. 2010 Mar;1192:376-84. doi: 10.1111/j.1749-6632.2009.05346.x. Review.

PMID:
20392263
37.

c-Cbl promotes T cell receptor-induced thymocyte apoptosis by activating the phosphatidylinositol 3-kinase/Akt pathway.

Thien CB, Dagger SA, Steer JH, Koentgen F, Jansen ES, Scott CL, Langdon WY.

J Biol Chem. 2010 Apr 2;285(14):10969-81. doi: 10.1074/jbc.M109.094920. Epub 2010 Feb 4.

38.

Unaltered negative selection and Treg development of self-reactive thymocytes in TCR transgenic Fyn-deficient mice.

Mamchak AA, Thien CB, Dagger SA, Lyandres J, Jiang S, Langdon WY, DeFranco AL.

Eur J Immunol. 2010 Feb;40(2):539-47. doi: 10.1002/eji.200939645.

39.

Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1.

Kojo S, Elly C, Harada Y, Langdon WY, Kronenberg M, Liu YC.

Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17847-51. doi: 10.1073/pnas.0904078106. Epub 2009 Oct 7.

40.

A TNF- and c-Cbl-dependent FLIP(S)-degradation pathway and its function in Mycobacterium tuberculosis-induced macrophage apoptosis.

Kundu M, Pathak SK, Kumawat K, Basu S, Chatterjee G, Pathak S, Noguchi T, Takeda K, Ichijo H, Thien CB, Langdon WY, Basu J.

Nat Immunol. 2009 Aug;10(8):918-26. doi: 10.1038/ni.1754. Epub 2009 Jul 13.

PMID:
19597496
41.

The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells.

Rathinam C, Thien CB, Langdon WY, Gu H, Flavell RA.

Genes Dev. 2008 Apr 15;22(8):992-7. doi: 10.1101/gad.1651408. Erratum in: Genes Dev. 2009 Sep 1;23(17):2116.

42.

The Cbl-b RING finger domain has a limited role in regulating inflammatory cytokine production by IgE-activated mast cells.

Oksvold MP, Dagger SA, Thien CB, Langdon WY.

Mol Immunol. 2008 Feb;45(4):925-36. Epub 2007 Sep 14.

PMID:
17868870
43.

Genetic ablation of the c-Cbl ubiquitin ligase domain results in increased energy expenditure and improved insulin action.

Molero JC, Turner N, Thien CB, Langdon WY, James DE, Cooney GJ.

Diabetes. 2006 Dec;55(12):3411-7.

44.

Cbl-b is a negative regulator of inflammatory cytokines produced by IgE-activated mast cells.

Gustin SE, Thien CB, Langdon WY.

J Immunol. 2006 Nov 1;177(9):5980-9.

45.
46.

Loss of c-Cbl RING finger function results in high-intensity TCR signaling and thymic deletion.

Thien CB, Blystad FD, Zhan Y, Lew AM, Voigt V, Andoniou CE, Langdon WY.

EMBO J. 2005 Nov 2;24(21):3807-19. Epub 2005 Oct 6.

47.

Negative regulation of PTK signalling by Cbl proteins.

Thien CB, Langdon WY.

Growth Factors. 2005 Jun;23(2):161-7. Review.

PMID:
16019438
48.

c-Cbl-deficient mice have reduced adiposity, higher energy expenditure, and improved peripheral insulin action.

Molero JC, Jensen TE, Withers PC, Couzens M, Herzog H, Thien CB, Langdon WY, Walder K, Murphy MA, Bowtell DD, James DE, Cooney GJ.

J Clin Invest. 2004 Nov;114(9):1326-33.

49.

Identification of 14-3-3zeta as an EGF receptor interacting protein.

Oksvold MP, Huitfeldt HS, Langdon WY.

FEBS Lett. 2004 Jul 2;569(1-3):207-10.

50.

UV-radiation-induced internalization of the epidermal growth factor receptor requires distinct serine and tyrosine residues in the cytoplasmic carboxy-terminal domain.

Oksvold MP, Thien CB, Widerberg J, Chantry A, Huitfeldt HS, Langdon WY.

Radiat Res. 2004 Jun;161(6):685-91.

PMID:
15161351

Supplemental Content

Loading ...
Support Center